Novacyt Q4 2025 Earnings Show Growth Amid Stock Decline
AI-generated from multiple sources. Verify before acting on this reporting.
PARIS, May 4 (Reuters) - Novacyt, a French biotechnology company specializing in liquid biopsy and companion diagnostics, reported fourth-quarter 2025 earnings that showed financial growth, even as its stock price declined on the news.
The company, which operates primarily in the United States and Europe, posted revenue figures that exceeded analyst expectations for the period ending December 31, 2025. The earnings release, filed with U.S. regulators, indicated a year-over-year increase in net sales driven by expanded adoption of its OncoBEAM and OncoCYCLE testing platforms. Management attributed the growth to strategic partnerships with major oncology centers and increased demand for non-invasive cancer monitoring tools.
Despite the positive financial results, shares of Novacyt fell approximately 4.2% in early trading on the Nasdaq. The decline followed the company's guidance for the upcoming fiscal year, which some market participants viewed as conservative relative to the strong quarterly performance. Novacyt projected a modest increase in operating expenses for 2026 as it ramps up clinical trials for its next-generation liquid biopsy assays.
The company's chief executive officer stated during the earnings call that the investment in research and development remains a top priority, even as the firm seeks to improve its profit margins. "We are seeing strong uptake in our core markets," the executive said, noting that the U.S. market continues to represent the largest portion of total revenue. However, the executive did not provide specific details regarding the timeline for regulatory approvals of new products currently in the pipeline.
Analysts have offered mixed reactions to the results. While some praised the company's ability to maintain growth in a competitive diagnostic sector, others expressed concern over the widening gap between revenue gains and net income. The stock's performance suggests investors are weighing the long-term potential of the company's technology against immediate profitability concerns.
Novacyt has not yet commented on the specific reasons for the stock price dip beyond standard market reactions to earnings guidance. The company is scheduled to host an investor conference later this month, where it may provide additional clarity on its strategic direction and financial outlook for the remainder of 2026.
The divergence between reported earnings and market reaction remains a focal point for investors as the biotechnology sector navigates shifting regulatory landscapes and evolving reimbursement policies. Novacyt's ability to translate its technological advancements into sustained profitability will likely be closely watched in the coming quarters.